Regarding the CD56- or CD66b-expressing monocyte subsets, cancer patients presented with a higher blood cell count of CD56+ monocytes compared to healthy controls, specifically at the early stages of tumor development, which could indicate that the tumor might downregulate CD56+ monocytes during progression [11]. This evidence concerns the gene NCAM1 and neoplasm.